AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.

AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.

New approval brings the medicine to an earlier treatment setting and a broader patient population.

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...

AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

London open The FTSE 100 is expected to open 20 points higher on Tuesday, having closed up 0.02% on Monday at 8,503.71.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...

Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors that results in 12 to 21% weight loss in patients with obesity; however ...

For over 200 years, the New England Journal of Medicine (NEJM) has brought important medical news to the world’s most influential physicians. The global medical community, physicians ...

London stocks were set to nudge lower at the open on Tuesday following heavy losses on the S&P 500 and the Nasdaq.